B. Jones

发表

Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6.

A. Alex, M. D. de Groot, M. Ackland, 1999, Journal of medicinal chemistry.

A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6.

A. Alex, M. D. de Groot, M. Ackland, 1999, Journal of medicinal chemistry.

Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.

D A Smith, D. Smith, B. Jones, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates

Dennis A. Smith, M. Ackland, B. Jones, 1997 .

DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

Barry C. Jones, Jeffrey R. Koup, Dennis A. Smith, 2004, Drug Metabolism and Disposition.

Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes.

D A Smith, D. Smith, Dennis A. Smith, 1992, Biochemical pharmacology.

A Laboratory-Specific Scaling Factor to Predict the In Vivo Human Clearance of Aldehyde Oxidase Substrates

S. Neuhoff, V. Pilla Reddy, I. Gardner, 2020, Drug Metabolism and Disposition.

An Investigation into the Prediction of the Plasma Concentration-Time Profile and Its Interindividual Variability for a Range of Flavin-Containing Monooxygenase Substrates Using a Physiologically Based Pharmacokinetic Modeling Approach

A. Srivastava, V. Reddy, B. Jones, 2018, Drug Metabolism and Disposition.

Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling

Hannah M Jones, Maurice Dickins, Barry C Jones, 2011, Clinical pharmacokinetics.

Predicting oral absorption and bioavailability.

Barry C Jones, H. van de Waterbeemd, B. Jones, 2003, Progress in medicinal chemistry.

Human cytochrome P450s: selectivity and measurement in vivo.

D. Smith, B. Jones, R. Hyland, 1998, Xenobiotica; the fate of foreign compounds in biological systems.

CYP-Mediated Sulfoximine Deimination of AZD6738

G. Scarfe, B. Jones, Chungang Gu, 2017, Drug Metabolism and Disposition.

Drug-drug interactions for UGT substrates: a pharmacokinetic explanation for typically observed low exposure (AUC i /AUC) ratios

Dennis A. Smith, J. Williams, J. Koup, 2004 .

An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver

Dennis A. Smith, B. Jones, '. RACHELC.HALLIDAY, 2006 .

Inhibition of p-nitrophenol hydroxylase in rat liver microsomes by small aromatic and heterocyclic molecules.

D. Smith, A. Gescher, B. Jones, 1994, Drug metabolism and disposition: the biological fate of chemicals.

In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole.

B. Jones, C. Emoto, K. Iwasaki, 2003, Drug metabolism and pharmacokinetics.

Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics

D. Walker, Dennis A. Smith, B. Jones, 1996, Medicinal research reviews.

Further considerations towards an effective and efficient oncology drug discovery DMPK strategy.

B. Jones, N. Colclough, D. Mcginnity, 2020, Current drug metabolism.

An Investigation into the Prediction of In Vivo Clearance for a Range of Flavin-containing Monooxygenase Substrates

A. Srivastava, V. Reddy, B. Jones, 2017, Drug Metabolism and Disposition.

An S‐warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N‐deacetylated amino acid metabolite as the primary perpetrator

R. Pehrson, Marie Brännström, B. Jones, 2017, British journal of clinical pharmacology.

Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs

B. Jones, A. Pike, Roshini Markandu, 2021, Drug Metabolism and Disposition.

Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics

D A Smith, D K Walker, D. Walker, 1996, Medicinal research reviews.

Potential role for P-glycoprotein in the nonproportional pharmacokinetics of UK-343,664 in man

D. A. Smith, D. Smith, K. Beaumont, 2001, Xenobiotica; the fate of foreign compounds in biological systems.

The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

D J Rance, R. Obach, F. Macintyre, 1997, The Journal of pharmacology and experimental therapeutics.

Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.

D A Smith, D. Smith, B. Jones, 2001, British journal of clinical pharmacology.

Maraviroc: in vitro assessment of drug-drug interaction potential.

Maurice Dickins, Claire Collins, B. Jones, 2008, British journal of clinical pharmacology.

Investigation into UDP-Glucuronosyltransferase (UGT) Enzyme Kinetics of Imidazole- and Triazole-Containing Antifungal Drugs in Human Liver Microsomes and Recombinant UGT Enzymes

N. Irvine, B. Jones, R. Hyland, 2010, Drug Metabolism and Disposition.

In vitro and in vivo glucuronidation of midazolam in humans.

B. Jones, R. Hyland, S. Kempshall, 2009, British journal of clinical pharmacology.

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control

D. Tweedie, R. Walsky, N. Hariparsad, 2017, Drug Metabolism and Disposition.

An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.

D A Smith, D. Smith, N. Kitteringham, 1995, British journal of clinical pharmacology.

Human Cytochromes P450 and Their Role in Metabolism-Based Drug-Drug Interactions

S. Clarke, B. Jones, 2001 .

Exploring concepts of in vitro time-dependent CYP inhibition assays

J. Mao, B. Jones, J. Kenny, 2014, Expert opinion on drug metabolism & toxicology.

Using in vitro methods to determine P450s responsible for metabolism and discrimination from other oxidative pathways

V. Reddy, B. Jones, T. E. Bapiro, 2020 .

An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point.

K. Youdim, K. Saunders, B. Jones, 2008, Journal of pharmaceutical and biomedical analysis.

Cytochrome P450 2J2: Potential Role in Drug Metabolism and Cardiotoxicity

A. Pointon, B. Jones, Meeta Solanki, 2018, Drug Metabolism and Disposition.

CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population

Jaran Eriksen, Barry C Jones, Leif Bertilsson, 2006, Pharmacogenetics and genomics.

Identification of the cytochrome P450 isoforms involved in the O-demethylation of 4-nitroanisole in human liver microsomes.

D. Smith, B. Jones, C. A. Tyman, 1997, Xenobiotica; the fate of foreign compounds in biological systems.

Lipophilicity in PK design: methyl, ethyl, futile

Han van de Waterbeemd, Dennis A. Smith, Barry C. Jones, 2001, J. Comput. Aided Mol. Des..

Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three‐Dimensional Spheroid Cultures of Primary Human Hepatocytes

Sabine U. Vorrink, M. Ingelman-Sundberg, V. Lauschke, 2020, Clinical pharmacology and therapeutics.

Utility of human/human-derived reagents in drug discovery and development: An industrial perspective.

H. van de Waterbeemd, B. Jones, R. Hyland, 2006, Environmental toxicology and pharmacology.

Development of a combined protein and pharmacophore model for cytochrome P450 2C9.

Barry C Jones, A. Alex, M. D. de Groot, 2002, Journal of medicinal chemistry.

Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase).

D A Smith, M. Tute, D. Smith, 1996, Drug metabolism and disposition: the biological fate of chemicals.

A performance evaluation of multiple classification models of human PEPT1 inhibitors and non‐inhibitors

Jurre J. Kamphorst, B. Jones, L. Cucurull-Sanchez, 2007 .

Investigation of the metabolism of felodipine using on-line liquid chromatography/UV diode array detection/atmospheric pressure chemical ionization mass spectrometry as a diagnostic tool

J. Todd, P. Macrae, B. Jones, 1993 .

Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug–drug interactions: using in vitro data as an aid to assess study power

Amin Rostami-Hodjegan, Geoffrey T Tucker, Trevor N Johnson, 2009, Pharmaceutical statistics.

Application of PBPK modelling in drug discovery and development at Pfizer

Kuresh Youdim, Hannah M Jones, Maurice Dickins, 2012, Xenobiotica; the fate of foreign compounds in biological systems.

Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach

T. Andersson, B. Jones, Kajsa P. Kanebratt, 2017, Drug Metabolism and Disposition.

Synthetic strategies to lower affinity for CYP2D6

D. Smith, B. K. Park, B. Jones, 1997, European journal of drug metabolism and pharmacokinetics.

Cytochrome P450 metabolism and inhibition: analysis for drug discovery.

Kuresh Youdim, Barry C Jones, K. Youdim, 2009, Progress in medicinal chemistry.

Induction of Cytochrome P450: Assessment in an Immortalized Human Hepatocyte Cell Line (Fa2N4) Using a Novel Higher Throughput Cocktail Assay

K. Youdim, B. Jones, R. Hyland, 2007, Drug Metabolism and Disposition.

Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics

Barry C. Jones, Dennis A. Smith, M. Ackland, 1997 .

Structure-activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)- 5-[2-[(3-substituted)-1-azetidinyl]ethyl]-2-piperidones. 1. Selective antagonists of the neurokinin-2 receptor.

B. Jones, D. Middleton, Sandra D. Newman, 2002, Journal of medicinal chemistry.

Do Drug Metabolism and Pharmacokinetic Departments Make Any Contribution to Drug Discovery?

Esther F. Schmid, Dennis A. Smith, B. Jones, 2002, Clinical pharmacokinetics.

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control

D. Tweedie, R. Walsky, M. Mohutsky, 2017, Drug Metabolism and Disposition.

Time dependent analysis of assay comparability: a novel approach to understand intra- and inter-site variability over time

Alan Clark, Susanne Winiwarter, Barry Jones, 2015, Journal of Computer-Aided Molecular Design.

Designing rapid onset selective serotonin re-uptake inhibitors. Part 3: Site-directed metabolism as a strategy to avoid active circulating metabolites: structure-activity relationships of (thioalkyl)phenoxy benzylamines.

M. Andrews, Malcolm C. Mackenny, D. Hepworth, 2008, Bioorganic & medicinal chemistry letters.